DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday. The firm set a “hold” rating on the stock.

A number of other equities research analysts have also recently issued reports on DBVT. HC Wainwright upped their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Down 2.2 %

Shares of NASDAQ:DBVT opened at $0.62 on Thursday. The stock has a market capitalization of $59.83 million, a PE ratio of -0.69 and a beta of 0.66. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $2.14. The firm has a fifty day moving average price of $0.74 and a 200 day moving average price of $0.90.

DBV Technologies’s stock is going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. 71.74% of the stock is owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.